---
title: 'Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory
  analyses from the EMPA-KIDNEY trial'
date: '2024-09-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39277784/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240916193848&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: SGLT2 inhibition reduces serum uric acid in patients with
  CKD with larger effects at higher eGFR and in the absence of diabetes. However,
  the effect on uric acid is modest and did not translate into reduced risk of gout
  in ...'
disable_comments: true
---
CONCLUSION: SGLT2 inhibition reduces serum uric acid in patients with CKD with larger effects at higher eGFR and in the absence of diabetes. However, the effect on uric acid is modest and did not translate into reduced risk of gout in ...